Ribomic Positions Itself As Latest Potential Achondroplasia Competitor

 
• By Alaric DeArment
  
Blue figurine
Ribomic announced positive Phase II results for umedaptanib pegol in achondroplasia, a rare disease that causes dwarfism. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D